Publicaciones destacadas

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target

Dobano-Lopez, Celia; Valero, Juan Garcia; Araujo-Ayala, Ferran; Nadeu, Ferran; Gava, Fabien;

(...)

Lopez-Guillermo, Armando; Magnano, Laura; Colomer, Dolors; Bezombes, Christine; Perez-Galan, Patricia.

Referencia:
Blood Cancer Journal 2024.
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

Valero, JG; Matas-Céspedes, A; Arenas, F; Rodriguez, V; Carreras, J;

(...)

Cid, MC; Campo, E; López-Guillermo, A; Colomer, D; Pérez-Galán, P.

Referencia:
Leukemia 2021.
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Vidal-Crespo, Anna; Matas-Cespedes, Alba; Rodriguez, Vanina; Rossi, Cedric; Valero, Juan G;

(...)

Bezombes, Christine; van Bueren, Jeroen Lammerts; Chiu, Christopher; Doshi, Parul; Perez-Galan, Patricia.

Referencia:
Haematologica 2020.
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma

Rossi C; Gravelle P; Decaup E; Bordenave J; Poupot M;

(...)

Klein C; Céspedes AM; Perez-Galan P; Fournié JJ; Bezombes C.

Referencia:
Oncoimmunology 2019.
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Esteve-Arenys, A; Valero, J G; Chamorro-Jorganes, A; Gonzalez, D; Rodriguez, V;

(...)

Martinez, A; Rymkiewicz, G; Perez-Galan, P; Lopez-Guillermo, A; Roue, G.

Referencia:
Oncogene 2018.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

(...)

Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

Referencia:
Haematologica 2017.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

(...)

Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

Referencia:
Clinical Cancer Research 2017.
The challenge of the microenvironment in mantle cell lymphoma

Pérez-Galán P.; Roué G.;

Referencia:
2015.
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

Matas-Cespedes, Alba; Rodriguez, Vanina; Kalko, Susana G; Vidal-Crespo, Anna; Rosich, Laia;

(...)

Campo, Elias; Roue, Gael; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.

Referencia:
Clinical Cancer Research 2014.
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Herman, S E M; Sun, X; Mcauley, E M; Hsieh, M M; Pittaluga, S;

(...)

Buggy, J J; Aue, G; Tisdale, J F; Perez-Galan, P; Wiestner, A.

Referencia:
Leukemia 2013.